Last viewed: VNDA


Prices are updated after-hours



nasdaq:VNDA Vanda Pharmaceuticals Inc.

VNDA | $4.57 -1.3% -1.31% 1.5M twitter stocktwits trandingview |
Health Technology

(0.0% 1d) (18.1% 1m) (-27.5% 1y) (0.0% 2d) (-1.5% 3d) (-10.8% 7d) (6.36% volume)
Earnings Calendar: 2023-02-22
Market Cap: $ 262,946,370

http://www.vandapharma.com
Sec Filling | Patents | 284 employees


Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

dermatitis   schizophrenia   nervous system   atopic dermatitis  

Drugs
Fanapt (iloperidone)
Hetlioz (tasimelteon)
Hetlioz LQ (tasimelteon)

add to watch list Paper trade email alert is off

Press-releases


Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA Litigation
Published: 2024-04-23 (Crawled : 14:30) - biospace.com/
VNDA | $4.57 -1.3% -1.31% 1.5M twitter stocktwits trandingview |
Health Technology
| | O: -5.84% H: 2.31% C: -2.73%

hetlioz pharmaceuticals
Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA Litigation
Published: 2024-04-22 (Crawled : 00:00) - prnewswire.com
VNDA | $4.57 -1.3% -1.31% 1.5M twitter stocktwits trandingview |
Health Technology
| | O: -5.84% H: 2.31% C: -2.73%

hetlioz pharmaceuticals
Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak
Published: 2024-04-17 (Crawled : 13:00) - prnewswire.com
VNDA | $4.57 -1.3% -1.31% 1.5M twitter stocktwits trandingview |
Health Technology
| | O: 35.5% H: 4.61% C: -3.32%

unsolicited pharmaceuticals
Future Pak Confirms Proposal to Acquire Vanda Pharmaceuticals for $7.25 to $7.75 Per Share in Cash
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
MC | $53.99 -1.12% 0.0% 840K twitter stocktwits trandingview |
Finance
| | O: 0.56% H: 0.8% C: -0.41%
VNDA | $4.57 -1.3% -1.31% 1.5M twitter stocktwits trandingview |
Health Technology
| | O: 35.5% H: 4.61% C: -3.32%

pharmaceuticals acquire for proposal
Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder
Published: 2024-04-02 (Crawled : 23:00) - biospace.com/
VNDA | $4.57 -1.3% -1.31% 1.5M twitter stocktwits trandingview |
Health Technology
| | O: -2.43% H: 0.0% C: -2.74%

fanapt fda approval treatment
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia
Published: 2024-03-06 (Crawled : 12:00) - prnewswire.com
VNDA | $4.57 -1.3% -1.31% 1.5M twitter stocktwits trandingview |
Health Technology
| | O: -1.21% H: 0.0% C: -4.4%

hetlioz fda update treatment pharmaceuticals
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-02-07 (Crawled : 21:00) - prnewswire.com
FNCTF | News | $11.16 -20.84% 130 twitter stocktwits trandingview |
Communications
| | O: -2.28% H: 0.0% C: 0.0%
JNJ | News | $148.53 -0.69% -0.14% 9.6M twitter stocktwits trandingview |
Health Technology
| | O: -0.63% H: 0.0% C: 0.0%
VNDA | $4.57 -1.3% -1.31% 1.5M twitter stocktwits trandingview |
Health Technology
| | O: 0.27% H: 20.82% C: 11.51%

year pharmaceuticals financial results
Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of Onychomycosis
Published: 2024-01-31 (Crawled : 14:30) - biospace.com/
VNDA | $4.57 -1.3% -1.31% 1.5M twitter stocktwits trandingview |
Health Technology
| | O: 1.37% H: 1.35% C: -2.7%

vtr-297 fda drug candidate approval treatment pharmaceuticals antifungal
Court Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag Hearing Request by March 5, 2024
Published: 2024-01-30 (Crawled : 00:00) - prnewswire.com
VNDA | $4.57 -1.3% -1.31% 1.5M twitter stocktwits trandingview |
Health Technology
| | O: 0.0% H: 0.26% C: -3.95%

fda resolve
Vanda Pharmaceuticals Announces a U.S. Patent Allowance for PONVORY® (ponesimod) in the U.S.
Published: 2024-01-26 (Crawled : 04:00) - prnewswire.com
JNJ | News | $148.53 -0.69% -0.14% 9.6M twitter stocktwits trandingview |
Health Technology
| | O: 0.8% H: 0.0% C: 0.0%
VNDA | $4.57 -1.3% -1.31% 1.5M twitter stocktwits trandingview |
Health Technology
| | O: 0.79% H: 1.05% C: -1.83%

ponvory patent pharmaceuticals
See all


Last 15 days Sec forms
File Id Form Published Date Transaction Date Direction Code Amount Transacted Owned Amount


Your Today's Watch List
Sign in to create a watchlist
Gainers vs Losers
62% 38%

Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M twitter stocktwits trandingview |
Consumer Services

BOF | $1.99 70.09% 41.21% 110M twitter stocktwits trandingview |

ILAG | $0.51 6.03% 40.62% 1.7M twitter stocktwits trandingview |

LICN | $0.941 68.04% 40.49% 15M twitter stocktwits trandingview |

AMST | $3.31 65.5% 39.58% 70M twitter stocktwits trandingview |
Technology Services

MTC | $3.615 61.38% 38.04% 9.3M twitter stocktwits trandingview |
Technology Services

WIMI | $1.15 58.53% 36.92% 19M twitter stocktwits trandingview |
Technology Services

AIH | $0.45 12.5% 30.92% 320K twitter stocktwits trandingview |
Health Services

MULN | News | $3.78 38.46% 27.78% 13M twitter stocktwits trandingview |
Information

RILY | $29.86 37.48% 27.26% 12M twitter stocktwits trandingview |
Finance


Last 48 Hours Insiders Buying
RKT P 347 | $12.55 -0.63% 0.48% 1.7M twitter stocktwits trandingview |
Finance
| 22:30
NWFL | News | $24.6 2.03% 1.99% 9.9K twitter stocktwits trandingview |
Finance
| 22:00
TGEN P 10000 | $0.685 39.71% 6.6K twitter stocktwits trandingview |
Utilities
| 20:01
MNSB P 310 | $15.88 -2.93% -3.02% 46K twitter stocktwits trandingview |
Finance
| 15:30
RMCF | $3.54 0.28% 7.1K twitter stocktwits trandingview |
Consumer Non-Durables
| 20:10

12 months watchlist earnings calendar